Reverse transcriptase-IN-1 NEW
| Price | $58 | $133 | $193 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-11 |
Product Details
| Product Name: Reverse transcriptase-IN-1 | CAS No.: 2380001-43-2 |
| Purity: 99.61% | Supply Ability: 10g |
| Release date: 2026/05/11 |
Product Introduction
Bioactivity
| Name | Reverse transcriptase-IN-1 |
| Description | Reverse transcriptase-IN-1 is a diarylbenzopyrimidine (DABP) analogue and a potent inhibitor of HIV-1 nonnucleoside reverse transcriptase with an IC50of 13.7 nM. |
| In vitro | Reverse transcriptase-IN-1 has antiviral activity with EC50 values of 3.4 nM, 4.3 nM and 3.6 nM for HIV-1 IIIB, E138K and K103N mutants, respectively[1]. |
| In vivo | The PK study and safety assessment of Reverse transcriptase-IN-1 shows that it is absorbed with mean residence times (MRTs) of 11.8 hours (5 mg/kg, p.o.) and 11.4 hours (1 mg/kg, i.v.) at these two doses. The Cmax of Reverse transcriptase-IN-1 is 39.9 ng/mL at a dose of 5 mg/kg. The oral bioavailability of Reverse transcriptase-IN-1 is significantly improved to 16.5% at a dose of 5 mg/kg in rats. The intrinsic rat microsome clearance of Reverse transcriptase-IN-1 is 33.2 μL/min/mg proteins[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (2.23 mM), Sonication is recommended. DMSO : 12 mg/mL (26.82 mM), Sonication and heating to 60℃ are recommended. |
| Keywords | Reverse transcriptase-IN-1 | Reverse transcriptaseIN1 | Reverse transcriptase IN 1 | Inhibitor | inhibit | Human immunodeficiency virus | HIVProtease | HIV-1 reverse transcriptase | HIV-1 | HIV Protease | HIV |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Emtricitabine | Dolutegravir intermediate-1 | Dimethyl fumarate | Lamivudine | Chloroquine phosphate | Valproic Acid | (-)-Epigallocatechin Gallate | Decanedioic acid | Dextran sulfate sodium salt (MW 5000) | Tenofovir |
| Related Compound Libraries | Bioactive Compound Library | Anti-Viral Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Anti-Infection Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1520.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-05-11 | |
| $95.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-05-26 | |
| $8470.00 |
VIP4Y
|
Dingwang Technology (Wuhan) Co., Ltd.
|
2025-08-22 | |
| $58.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-04-20 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY